WO1995005196B1 - Traitement de l'infection par vih a base d'anticorps - Google Patents
Traitement de l'infection par vih a base d'anticorpsInfo
- Publication number
- WO1995005196B1 WO1995005196B1 PCT/US1994/008312 US9408312W WO9505196B1 WO 1995005196 B1 WO1995005196 B1 WO 1995005196B1 US 9408312 W US9408312 W US 9408312W WO 9505196 B1 WO9505196 B1 WO 9505196B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- antibody
- antigen
- complexes
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
Une démarche pour ralentir ou prévenir la progression de l'infection par VIH chez un sujet exposé à ce virus et pour prévenir l'infection par VIH chez un sujet à risque d'infection par ce virus, consiste à administrer audit sujet un complexe anticorps-antigène ou un complexe anticorps-antigène-complément dans des dosages suffisants pour empêcher par voie compétitive les complexes du VIH de se lier aux cellules par l'intermédiaire des récepteurs de Fc ou des récepteurs du complément dans le tissu lymphoïde. Cette démarche met en ÷uvre des anticorps qui se fixent sur des antigènes cellulaires pour produire des complexes antigènes-anticorps et/ou des complexes antigènes-anticorps-complément, qui à leur tour inhibent ou empêchent la fixation de complexes VIH-anticorps ou de complexes VIH-anticorps-complément ou bien de complexes VIH-complément sur des cellules dans le tissu lymphoïde. La limitation de la concentration des complexes du VIH fixés sur le tissu lymphoïde permet de diminuer la charge en cellules infectées par virus, ce qui accroît l'efficacité des agents anti-rétroviraux ainsi que l'inactivation du virus dans la circulation sanguine. Par ailleurs, la concentration réduite ou l'absence du VIH dans le tissu lymphoïde entrave l'infection des lymphocytes T CD4+ présentes.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002169370A CA2169370A1 (fr) | 1993-08-13 | 1994-08-10 | Traitement de l'infection par le vih a l'aide d'anticorps |
| EP94925684A EP0715522A1 (fr) | 1993-08-13 | 1994-08-10 | Traitement de l'infection par vih a base d'anticorps |
| AU75504/94A AU703324B2 (en) | 1993-08-13 | 1994-08-10 | Antibody-based treatment of HIV infection |
| NO960551A NO960551D0 (no) | 1993-08-13 | 1996-02-12 | Antistoff basert behandling av HIV infeksjon |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10558493A | 1993-08-13 | 1993-08-13 | |
| US08/105,584 | 1993-08-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1995005196A1 WO1995005196A1 (fr) | 1995-02-23 |
| WO1995005196B1 true WO1995005196B1 (fr) | 1995-05-04 |
Family
ID=22306655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/008312 Ceased WO1995005196A1 (fr) | 1993-08-13 | 1994-08-10 | Traitement de l'infection par vih a base d'anticorps |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0715522A1 (fr) |
| AU (1) | AU703324B2 (fr) |
| CA (1) | CA2169370A1 (fr) |
| NO (1) | NO960551D0 (fr) |
| WO (1) | WO1995005196A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993812A (en) * | 1995-09-14 | 1999-11-30 | Cangene Corporation | Method of delaying the progression of an infection with the human immunodeficiency virus |
| JP2009525319A (ja) | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1168152A (fr) | 1981-10-20 | 1984-05-29 | Winnipeg Rh Institute Inc. (The) | Procede de preparation de fractions de plasma humain contenant des immunoglobulines |
| WO1991006575A1 (fr) * | 1989-11-03 | 1991-05-16 | Repligen Corporation | Anticorps monoclonal humain specifique du vih-1 |
-
1994
- 1994-08-10 CA CA002169370A patent/CA2169370A1/fr not_active Abandoned
- 1994-08-10 EP EP94925684A patent/EP0715522A1/fr not_active Ceased
- 1994-08-10 AU AU75504/94A patent/AU703324B2/en not_active Ceased
- 1994-08-10 WO PCT/US1994/008312 patent/WO1995005196A1/fr not_active Ceased
-
1996
- 1996-02-12 NO NO960551A patent/NO960551D0/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tyler et al. | Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. | |
| Baldwin et al. | Significance of serum factors modifying cellular immune responses to growing tumours | |
| Jansen et al. | Cell markers in hairy cell leukemia studied in cells from 51 patients | |
| Ashida et al. | Lymphocyte major histocompatibility complex-encoded class II structures may act as sperm receptors. | |
| Lamon et al. | IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells | |
| Gajl-Peczalska et al. | B-cell markers on lymphoblasts in acute lymphoblastic leukaemia | |
| Yefenof et al. | Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines | |
| EP0248534A3 (fr) | Méthode pour détecter une infection provoquée par le virus SIDA | |
| Hutt-Fletcher et al. | Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d. | |
| WO1995005196B1 (fr) | Traitement de l'infection par vih a base d'anticorps | |
| Wright et al. | Allograft tolerance: presumptive evidence that serum factors from tolerant animals that block lymphocyte-mediated immunity in vitro are soluble antigen-antibody complexes | |
| Magee et al. | Macrophage colony-stimulating factor enhances the expression of Fc receptors on murine peritoneal macrophages | |
| Dathan et al. | Nephrotic syndrome in chronic lymphocytic leukaemia | |
| Cohen | Porphyria cutanea tarda in human immunodeficiency virus-seropositive men: case report and literature review | |
| Mouhoub et al. | Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV‐infected cells | |
| Dienstag et al. | Abnormalities of lymphocyte regulation in primary biliary cirrhosis | |
| Strnad et al. | Biochemical identification of primate lymphoid cell‐surface glycoproteins | |
| Gormus et al. | Heterogeneity of human lymphocyte Fc receptors. II. Relationship to antibody-dependent, cell-mediated cytotoxicity | |
| Schrempf‐Decker et al. | Biological and immunological characterization of a human liver immunoregulatory protein | |
| Gerhartz et al. | Spontaneous Epstein-Barr virus transformed B-cell line sharing the identical immunoglobulin gene rearrangement with acute myeloid leukemia | |
| Kurrle et al. | T cell activation by CD3 antibodies | |
| MacLeod | The blood transfusion effect: clinical aspects | |
| Miller et al. | Protein A adsorption of acute myelogenous leukemia serum induces in vitro blast lysis | |
| Cassuto et al. | Mycosis fungoides associated with Mediterranean lymphoma | |
| Suga et al. | Human immunodeficiency virus type-1 envelope glycoprotein gp120 induces expression of fusion regulatory protein (FRP)-1/CD98 on CD4+ T cells: a possible regulatory mechanism of HIV-induced syncytium formation |